Effects of phosphoinositide 3-kinase inhibitor on the proliferation and migration of triple-negative breast cancer cell lines

TANG Xiaofei; JIANG Lihua; ZENG Fanxin; FU Jiemin; DONG Zhi

您当前的位置：

首页 >

文章列表页 >

Effects of phosphoinositide 3-kinase inhibitor on the proliferation and migration of triple-negative breast cancer cell lines

更新时间：2023-12-18

- Effects of phosphoinositide 3-kinase inhibitor on the proliferation and migration of triple-negative breast cancer cell lines
- Journal of Chongqing Medical University Vol. 36, Issue 5, Pages: 478-482(2013)
- 作者机构：
  
  1. 重庆医科大学生物化学与分子药理学重点实验室,重庆,400016
  2. 重庆复创医药研究有限公司药理与毒理实验室,重庆,400061
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2013，
扫描看全文
TANG Xiaofei, JIANG Lihua, ZENG Fanxin, et al. Effects of phosphoinositide 3-kinase inhibitor on the proliferation and migration of triple-negative breast cancer cell lines. [J]. Journal of Chongqing Medical University 36(5):478-482(2013)
DOI：

TANG Xiaofei, JIANG Lihua, ZENG Fanxin, et al. Effects of phosphoinositide 3-kinase inhibitor on the proliferation and migration of triple-negative breast cancer cell lines. [J]. Journal of Chongqing Medical University 36(5):478-482(2013) DOI：

摘要

目的：为了研究磷脂酰肌醇3激酶（phosphoinositide 3 kinase，PI3K）抑制剂单用及其联合表皮生长因子受体（epidermal growth factor receptor，EGFR）抑制剂对三阴性乳腺癌（triple-negative breast cancer，TNBC）细胞增殖、迁移的影响。方法：通过细胞增殖实验、克隆形成实验、细胞划痕愈合实验、流式细胞仪以及ELISA实验来分析PI3K抑制剂PF-04691502（以下简写为PF）单用或与EGFR抑制剂吉非替尼联合抗TNBC细胞（HCC1937和MDA-MB 231）增殖、迁移的的影响。结果：PF可显著抑制TNBC细胞的增殖，对TNBC细胞克隆的形成、迁移和蛋白激酶Ｂ[（protein kinase B，PKB），又名Akt]的磷酸化均有显著抑制作用（P<0.0５），并可将TNBC细胞阻滞于G1期（P<0.0５）。小剂量PF联合EGFR抑制剂吉非替尼可协同抑制TNBC细胞的增殖、克隆形成、迁移及Akt的磷酸化。结论：PI3K抑制剂单用可显著抑制TNBC细胞的增殖、克隆形成和迁移，与EGFR抑制剂合用可形成明显的协同效应。其作用机制可能与其降低Akt磷酸化水平及G1期细胞周期阻滞作用有关。

Abstract

Objective：To study the effects of phosphoinositide 3kinase（PI3K） inhibitor alone and in combination with epidermal growth factor receptor（EGFR） inhibitor on the proliferation and migration of triple-negative breast cancer（TNBC） cell lines. Meth－ods：Effects of PF-04691502（PF），a PI3K inhibitor，alone or in combination with gefitinib，a EGFR inhibitor，on the proliferation and migration of TNBC cell lines（HCC1937 and MDA-MB 231） were measured by the proliferation，colony formation，wound-healing，flow cytometry and ELISA. Results：PF prevented the proliferation，colony formation and migration of TNBC cell lines，inhibited the protein kinase B（ＰＫＢ or Akt） phosphorylation of these cell lines and retarded the cells in G1 phase（P<0.0５）. Significant synergistic effects were observed when in combination with gefitinib，a EGFR inhibitor. Conclusions：PI3K inhibitor when used alone could pre－vent the proliferation，colony formation and migration of TNBC cell lines and when used in combination with EGFR inhibitors could form significant synergistic effects，mechanisms of which may relate with it’s inhibition of Akt phosphorylation and G1 phase arrest.

关键词

磷脂酰肌醇3激酶三阴性乳腺癌靶向治疗表皮生长因子受体吉非替尼联合治疗

Keywords

phosphoinositide 3kinasetriple-negative breast cancertarget therapyepidermal growth factor receptorgefitinibcom－bined therapy

references

Views

558

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Study on the sensitizing effect of SCR7 on cisplatin chemotherapy in triple-negative breast cancer

Efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with docetaxel monotherapy in previously treated advanced non-small-cell lung cancer:a Meta-analysis

Effect of connexin 43 on the primary resistance to gefitinib in non-small-cell lung cancer cells

Expressions of proliferating cell nuclearantigen, estrogen receptor and epidermal growth factor receptor in tumors of the gallbladder

Related Author

Wang Xiumei

Pan Haiting

Qi Ye

Jiang Youfan

Jiang Depeng

Yang Yingqing

Yang Jie

Qin Guihui

Related Institution

Department of Internal Oncology，People's Hospital of Inner Mongolia Medical University

Teaching and Research Section of Immunology，School of Basic Medical Sciences，Inner Mongolia Medical University

Department of Respiratory Diseases,the Second Affiliated Hospital,Chongqing Medical University

Department of Pharmacology,School of Pharmacy,Guangxi Medical University

Department of Oral and Maxillofacial Surgery，the First Affiliated Hospital，Chongqing Medical University

⁰